Skip to main content
. 2019 Jun 14;39(4):998–1016. doi: 10.1148/rg.2019180178

Figure 7a.

Figure 7a.

Metastatic clear cell RCC in a 53-year-old man undergoing therapy with nivolumab with oligoprogression. (a, b) Axial contrast-enhanced CT images through the lower chest and upper abdomen before the initiation of nivolumab show several extrapleural metastases in the right hemithorax (arrow). The patient subsequently received nivolumab. (c, d) Axial contrast-enhanced MR images acquired 6 months after therapy show that most of the lesions decreased in size substantially (arrow in d), but one of the metastases had enlarged (arrow in c). Another extrapleural metastasis had resolved (not shown). (e) Axial contrast-enhanced MR image from an examination after radiation therapy was performed for the enlarging lesion shows a decrease in size and enhancement of the right chest wall lesion (arrow). The patient continued to take nivolumab for an additional 6 months.